05:34 PM EDT, 10/09/2025 (MT Newswires) -- Phibro Animal Health ( PAHC ) said late Thursday it has signed a licensing agreement with Lighthouse Pharmaceuticals to develop and commercialize a new therapeutic compound aimed at improving periodontal health in companion animals.

Financial details weren't disclosed.

The deal grants Phibro exclusive global rights to develop, manufacture, and market Lighthouse's proprietary canine periodontal treatment, which has shown strong preclinical safety and efficacy in targeting periodontal disease in dogs.

Phibro said it will oversee all regulatory, commercial, and distribution efforts worldwide, using its existing infrastructure and relationships in the veterinary market.